Fair Value Calculator Fair Value Calculator
EN DE

0775 (0775) Fair Value & Analysis

Healthcare · Market cap HK$5.5B

0 0775 0775 · HK
PriceHK$0.5700
Fair ValueHK$0.2600
Upside-54.4%
Quality36/100
Evidence: Low Range HK$0.2000 – HK$0.3900

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −21.9% over the past month.

Price vs Fair Value (12 months)

HK$1.03 HK$0.5700 Fair Value HK$0.2600 Jun 2025 Jun 2026

12‑month range HK$0.5700 – HK$1.03 · fair‑value band HK$0.2000 – HK$0.3900 · the HK$0.5700 price screens above the HK$0.2600 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0775 (0775) currently trades at HK$0.5700, while our model-based Fair Value estimate is HK$0.2600 — implying the stock looks roughly 54.4% overvalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 0775 generated revenue of HK$5.4B at a net margin of -3.5%. Revenue declined 2.9% year over year. It earns a return on equity of -5.1%. Net debt stands at HK$6.0B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$5.4B
Revenue growth (YoY) -2.9%
Net margin -3.5%
Return on equity -5.1%
Free cash flow −HK$278M FY2025
Operating margin -3.5%
More key figures
EPS (TTM) HK$-0.0200
EPS growth (YoY) -97.3%
Net debt HK$6.0B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0775 reported revenue of HK$5.4B in FY2025 versus HK$5.4B in FY2021, a compound +0.0%/yr. Reported net income was −HK$188M in FY2025.

Revenue +0.0%/yr
FY21 HK$5.4B
FY22 HK$5.3B
FY23 HK$5.3B
FY24 HK$5.5B
FY25 HK$5.4B
Net income
FY21 HK$163M
FY22 HK$132M
FY23 HK$17.3M
FY24 −HK$127M
FY25 −HK$188M

Is 0775 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX 7,746 MXN 449.62 MXN -94%
Regeneron Pharmaceuticals, Inc REGN $601.65 $577.20 -4%
UCB SA UCB €251.70 €180.06 -28%
argenx SE ARGNF $900.00 $382.64 -57%
Alnylam Pharmaceuticals, Inc ALNY $288.18 $51.70 -82%
Samsung Biologics Co 207940 1,000,000 KRW 724,332 KRW -28%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 0775 (0775) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.2600 versus a price of HK$0.5700 — about −54% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 0775?
Our model-based fair value for 0775 is HK$0.2600 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.5700.
What is the quality score of 0775?
0775 has a Quality Score of 36/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 0775 (0775)?
0775 reported trailing-twelve-month revenue of about HK$5.4B (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 0775?
The net profit margin of 0775 is about -3.5%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.